Nuvation gets in before Nuvalent
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
Akeso looks early in small-cell lung cancer
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
Avenzo takes a second shot at CDK-selective inhibition
AVZO-023 follows AVZO-021 into clinical trials.
